The mechanism of Cangfu Daotan Decoction in polycystic ovary syndrome based on NEK7-NLRP3 inflammasome signaling pathway

Phase 1

• Conditions: Polycystic Ovary Syndrome

• Registration Number: ITMCTR2200005611
• Lead Sponsor: Affiliated Hospital of Shandong University of Traditional Chinese Medicine

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 20 February 2023

Recruitment & Eligibility

• Status: Pending
• Sex: Female
• Target Recruitment: Not specified

Inclusion Criteria

1. Phlegm-damp type PCOS patients
?In line with the diagnostic criteria of Chinese and Western medicine for phlegm-damp PCOS;
?Body Mass Index (BMI) = 27kg/m2;
?Age between 20 and 35 years old;
?Have signed the informed consent.
2. Non-phlegm-damp PCOS patients
?Comply with the western medicine diagnostic standards of PCOS;
? BMI is 18~26kg/m2;
?Age between 20 and 35 years old;
?Have signed the informed consent.
3. Normal control group patients
? Those who practice assisted reproductive technology due to male factors;
?BMI is 18~26kg/m2;
?Age between 20 and 35 years old;
?Have signed the informed consent.

Exclusion Criteria

1. Age < 20 years old or age > 35 years old;
2. Suffering from other diseases that can cause ovulation disorders or hyperandrogenism, such as hyperprolactinemia, Cushing's syndrome, congenital adrenal hyperplasia, etc.;
3. Combined with other systemic diseases and inflammatory diseases, such as diabetes, hyperthyroidism, heart disease, etc.;
4. Those with a history of recurrent miscarriage;

Study & Design

• Study Type: Interventional study
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
caspase-1;apoptosis - associatedspeck-like protein containing a CARD(ASC);IL-18;IL-1b;pyrin domain containing 3 (NLRP3);NEK7;

Secondary Outcome Measures

Name	Time	Method
Body Mass Index(BMI);anti-Müllerian hormone(AMH);Luteinizing hormone(LH);follicle stimulating hormone(FSH);testosterone(T);